Shopping Cart
- Remove All
- Your shopping cart is currently empty
A-9758 is a RORγ ligand and selective RORγt inverse agonist (IC50: 5 nM) that effectively suppresses IL-17A release, Th17 differentiation, and Th17 effector function, significantly attenuating IL-23 driven psoriasiform dermatitis.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $2,570 | 10-14 weeks | |
50 mg | $3,380 | 10-14 weeks | |
100 mg | $4,600 | 10-14 weeks |
Description | A-9758 is a RORγ ligand and selective RORγt inverse agonist (IC50: 5 nM) that effectively suppresses IL-17A release, Th17 differentiation, and Th17 effector function, significantly attenuating IL-23 driven psoriasiform dermatitis. |
Targets&IC50 | RORβ:1370 nM , RORγt:5 nM , RORα:73 nM |
In vitro | A-9758 inhibits RORγ transactivation in humans, mice, dogs, and rats (IC50s: 38 nM, 20 nM, 25 nM, and 64 nM, respectively). It exhibits a cofactor profile by recruiting co-repressors [NCoR1: EC50 = 60 nM, NCoR2: EC50 = 43 nM] and derecruiting co-activators [NCoA1: IC50 = 110 nM, PGC1α: IC50 = 49 nM]. A-9758 inhibits TCR-mediated IL-17A secretion with IC50s of 100 nM and 38 nM for human CD4+ T cells and in vitro differentiated mouse Th17 cells, respectively, and attenuates the differentiation and/or effector function of RORγt-expressing Th17 cells. |
Molecular Weight | 527.36 |
Formula | C25H23Cl2F3N2O3 |
Cas No. | 2055271-22-0 |
Relative Density. | 1.44 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.